| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/09/2009 | WO2009043524A2 Use of a peptide as therapeutic agent |
| 04/09/2009 | WO2009043523A2 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 04/09/2009 | WO2009043522A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043521A2 Use of urocortin iii and urocortin i as therapeutic agents |
| 04/09/2009 | WO2009043520A1 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| 04/09/2009 | WO2009043519A2 Use of band 3 protein and pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043507A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043506A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043505A2 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer |
| 04/09/2009 | WO2009043504A2 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer |
| 04/09/2009 | WO2009043481A2 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043479A2 Use of eaa-mart1 (26-35) for the treatment of human cytomegalovirus infections |
| 04/09/2009 | WO2009043478A2 Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043469A2 Use of pneumadin as a therapeutic agent |
| 04/09/2009 | WO2009043468A2 Use of corticotropin-releasing factor as a therapeutic agent |
| 04/09/2009 | WO2009043467A1 U e of urocortin and corticotropin-releasing fact r as therapeutic agents |
| 04/09/2009 | WO2009043466A2 Therapeutic use of the peptide gluten exorphin a5 |
| 04/09/2009 | WO2009043465A2 Use of beta-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043462A1 Use of neuropeptide af as a therapeutic agent |
| 04/09/2009 | WO2009043461A1 Use of a hnp-1 defensin peptide, alone or in combination with neuropeptide af, as a therapeutic agent |
| 04/09/2009 | WO2009043460A1 Use of alpha-endorphin as a therapeutic agent |
| 04/09/2009 | WO2009043459A1 Use of a platelet fibrinogen receptor hexapeptide antagonist and alpha-endorphin as therapeutic agents |
| 04/09/2009 | WO2009043458A2 Use of oxytocin to treat many diseases |
| 04/09/2009 | WO2009043457A2 Use of human hemokinin-1 and optionally oxytocin to treat diseases involving excessive angiogenesis |
| 04/09/2009 | WO2009043456A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043455A2 Therapeutic uses of angiogenin 108-122 and gluten exorphin a5 |
| 04/09/2009 | WO2009043454A2 Use of pacap-27 as a therapeutic agent |
| 04/09/2009 | WO2009043452A1 Use of rfrp, alone or in combination with neurokinin-b, as a therapeutic agent |
| 04/09/2009 | WO2009043449A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043447A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043441A1 D-ala-gln-octadecyl ester as a therapeutic agent |
| 04/09/2009 | WO2009043440A2 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 04/09/2009 | WO2009043439A2 Use of retrocyclin- 1 as a therapeutic agent for the treatment of hcmv infections |
| 04/09/2009 | WO2009043437A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/09/2009 | WO2009043436A2 Use of af12198 as a therapeutic agent |
| 04/09/2009 | WO2009043296A1 Gambogic glycoside derivatives and analogs, the preparation and the application thereof |
| 04/09/2009 | WO2009043226A1 A stable liquid composition comprising taxan derivatives and its preparation method. |
| 04/09/2009 | WO2009043223A1 The chiral ruthenium complexes and their use as anti-tumor drug |
| 04/09/2009 | WO2009043166A1 An anti-cancer cytotoxic monoclonal antibody |
| 04/09/2009 | WO2009043116A1 Methods and compositions for the treatment of phosphatase- related disorders |
| 04/09/2009 | WO2009043114A1 Arsenoxide compound and method of use |
| 04/09/2009 | WO2009043093A1 Hif inhibition |
| 04/09/2009 | WO2009023845A3 Combination therapy with synthetic triterpenoids and gemcitabine |
| 04/09/2009 | WO2009020521A3 Identification and treatment of estrogen responsive prostate tumors |
| 04/09/2009 | WO2009015233A3 Gefitinib sensitivity-related gene expression and products and methods related thereto |
| 04/09/2009 | WO2009012785A3 Complexes of an emulgator and a fatty acid |
| 04/09/2009 | WO2009012784A3 Methods for preparing cytotoxic complexes of emulsifier and fatty acid |
| 04/09/2009 | WO2009010290A3 Engineered anti-alpha v- integrin hybrid antibodies |
| 04/09/2009 | WO2009010287A3 Specific therapy and medicament using integrin ligands for treating cancer |
| 04/09/2009 | WO2009007427A3 Novel antibodies inhibiting c-met dimerization, and uses thereof |
| 04/09/2009 | WO2008155666A3 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| 04/09/2009 | WO2008148867A3 Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of janus kinases |
| 04/09/2009 | WO2008138904A3 Rna antagonist compounds for the modulation of her3 |
| 04/09/2009 | WO2008135259A3 Antibody molecule composition |
| 04/09/2009 | WO2008122667A3 Ureylene derivatives |
| 04/09/2009 | WO2008074997A8 Pyridine benzamides and pyrazine benzamides used as pkd inhibitors |
| 04/09/2009 | WO2008060535A3 Use of reversine and analogs for treatment of cancer |
| 04/09/2009 | WO2008023266A3 Kiwi extract |
| 04/09/2009 | US20090094715 Methods of use of antibodies with reduced immunogenicity or toxicity |
| 04/09/2009 | US20090093617 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 04/09/2009 | US20090093546 Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators |
| 04/09/2009 | US20090093543 Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production |
| 04/09/2009 | US20090093540 Anti-tumor composition |
| 04/09/2009 | US20090093539 Anti-angiogenic compositions and methods of use thereof |
| 04/09/2009 | US20090093538 Method for treating cancer |
| 04/09/2009 | US20090093536 Pharmaceutical composition comprising thiacremonone for preventing or treating cancer |
| 04/09/2009 | US20090093518 Piperidinyl-substituted isoquinolone derivatives |
| 04/09/2009 | US20090093507 Cdk inhibitors containing a zinc binding moiety |
| 04/09/2009 | US20090093495 Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases |
| 04/09/2009 | US20090093494 4-Pyrimidineamine Compounds And Uses As Anti-Proliferative Agents |
| 04/09/2009 | US20090093493 1-phenylalcoxy-2-beta-phenylethyl derivatives as p-glycoprotein (p-gp) inhibitors useful in drug resistance events |
| 04/09/2009 | US20090093489 Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| 04/09/2009 | US20090093479 Anti-cancer agents and uses thereof |
| 04/09/2009 | US20090093478 N-aroyl cyclic amines |
| 04/09/2009 | US20090093467 Therapeutic compositions and methods |
| 04/09/2009 | US20090093459 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof |
| 04/09/2009 | US20090093455 Quinolone analogs and methods related thereto |
| 04/09/2009 | US20090093452 Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| 04/09/2009 | US20090093444 Cathepsin Cysteine Protease Inhibitors |
| 04/09/2009 | US20090093433 SENSE mRNA THERAPY |
| 04/09/2009 | US20090093429 Combination therapy for treating cancer |
| 04/09/2009 | US20090093424 Markers for melanoma |
| 04/09/2009 | US20090093413 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093412 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/09/2009 | US20090093402 Albumin Fusion Proteins |
| 04/09/2009 | US20090093400 Truncated keratinocyte growth factor (KGF) having increased biological activity |
| 04/09/2009 | US20090093393 Methods For Selective Targeting |
| 04/09/2009 | US20090092684 Small molecule antagonists of bcl-2 family proteins |
| 04/09/2009 | US20090092675 Compositions containing multiple polymers and particles made using the compositions |
| 04/09/2009 | US20090092662 Liposome formulations of boronic acid compounds |
| 04/09/2009 | US20090092652 Method for the inhibition of angiogenesis or cancer using protective antigen related molecules |
| 04/09/2009 | US20090092650 Sustained Delivery Formulations of Octreotide Compounds |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092610 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 04/09/2009 | US20090092603 Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| 04/09/2009 | US20090092601 HUMANIZED ANTI-LT-beta-R ANTIBODIES |
| 04/09/2009 | US20090092600 Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| 04/09/2009 | US20090092596 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| 04/09/2009 | US20090092589 Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains |
| 04/09/2009 | US20090092546 Carrier molecules |